Jinhe Biotechnology CO., LTD. (SHE:002688)
China · Delayed Price · Currency is CNY 6.34
+0.05 (0.79%)
Feb 4, 2026, 3:04 PM CST
SHE:002688 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,745 | 2,366 | 2,168 | 2,117 | 2,072 | 1,808 |
Other Revenue | 4.99 | 4.99 | 6.04 | 5.82 | 5.8 | 6.56 |
| 2,750 | 2,371 | 2,174 | 2,123 | 2,078 | 1,815 | |
Revenue Growth (YoY) | 21.58% | 9.04% | 2.42% | 2.15% | 14.51% | 1.81% |
Cost of Revenue | 1,882 | 1,641 | 1,572 | 1,545 | 1,472 | 1,216 |
Gross Profit | 867.44 | 729.97 | 602.51 | 577.47 | 605.66 | 598.34 |
Selling, General & Admin | 480.24 | 401.98 | 367.95 | 352.78 | 316.37 | 308.49 |
Research & Development | 122.95 | 94 | 74 | 82.28 | 72.25 | 66.36 |
Other Operating Expenses | 10.83 | 8.14 | 5.82 | 7.75 | 12.15 | 12.27 |
Operating Expenses | 625.92 | 518.11 | 454.08 | 444.34 | 402.65 | 387.4 |
Operating Income | 241.51 | 211.85 | 148.43 | 133.13 | 203.01 | 210.94 |
Interest Expense | -88.86 | -80.34 | -60.03 | -36.41 | -52.34 | -60.35 |
Interest & Investment Income | 5.16 | 6.9 | 8.37 | 1.9 | 1.72 | 9.48 |
Currency Exchange Gain (Loss) | 8.92 | 8.92 | 8.85 | 40.34 | -8.83 | -31.58 |
Other Non Operating Income (Expenses) | -27.27 | -28.48 | -7.33 | -15.79 | -4.87 | -2.74 |
EBT Excluding Unusual Items | 139.47 | 118.85 | 98.29 | 123.18 | 138.68 | 125.77 |
Impairment of Goodwill | -39.77 | -39.77 | -5.62 | -7.74 | -11.04 | -8.31 |
Gain (Loss) on Sale of Investments | -1.6 | -1.22 | -1.52 | -3.94 | - | - |
Gain (Loss) on Sale of Assets | 0.26 | 0.19 | -0.36 | -0.25 | 4.87 | - |
Asset Writedown | 15.13 | -1.11 | -0.93 | -0.46 | -1.28 | -2.56 |
Other Unusual Items | 20.83 | 20.83 | 11.65 | 8.05 | 11.69 | 26 |
Pretax Income | 134.32 | 97.78 | 101.5 | 118.84 | 142.91 | 140.91 |
Income Tax Expense | 28.29 | 13.46 | 7.06 | 0.73 | 20.82 | 1.71 |
Earnings From Continuing Operations | 106.04 | 84.32 | 94.43 | 118.11 | 122.09 | 139.19 |
Minority Interest in Earnings | 19.47 | 15.88 | -7.98 | -42.5 | -28.1 | -21.87 |
Net Income | 125.51 | 100.2 | 86.46 | 75.62 | 93.99 | 117.32 |
Net Income to Common | 125.51 | 100.2 | 86.46 | 75.62 | 93.99 | 117.32 |
Net Income Growth | 29.18% | 15.90% | 14.34% | -19.55% | -19.89% | -36.56% |
Shares Outstanding (Basic) | 769 | 774 | 780 | 780 | 696 | 652 |
Shares Outstanding (Diluted) | 769 | 774 | 780 | 780 | 696 | 652 |
Shares Change (YoY) | -1.32% | -0.76% | -0.01% | 12.16% | 6.74% | 2.21% |
EPS (Basic) | 0.16 | 0.13 | 0.11 | 0.10 | 0.14 | 0.18 |
EPS (Diluted) | 0.16 | 0.13 | 0.11 | 0.10 | 0.14 | 0.18 |
EPS Growth | 30.91% | 16.79% | 14.34% | -28.27% | -24.94% | -37.93% |
Free Cash Flow | 144.54 | 136.18 | -258.45 | -277.69 | -230.74 | 54.07 |
Free Cash Flow Per Share | 0.19 | 0.18 | -0.33 | -0.36 | -0.33 | 0.08 |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | - | 0.100 |
Dividend Growth | - | - | - | - | - | -60.00% |
Gross Margin | 31.55% | 30.79% | 27.71% | 27.20% | 29.15% | 32.97% |
Operating Margin | 8.78% | 8.94% | 6.83% | 6.27% | 9.77% | 11.63% |
Profit Margin | 4.57% | 4.23% | 3.98% | 3.56% | 4.52% | 6.46% |
Free Cash Flow Margin | 5.26% | 5.75% | -11.89% | -13.08% | -11.10% | 2.98% |
EBITDA | 435.95 | 397.04 | 321.3 | 282.31 | 333.98 | 330.9 |
EBITDA Margin | 15.86% | 16.75% | 14.78% | 13.30% | 16.07% | 18.23% |
D&A For EBITDA | 194.43 | 185.19 | 172.86 | 149.18 | 130.97 | 119.95 |
EBIT | 241.51 | 211.85 | 148.43 | 133.13 | 203.01 | 210.94 |
EBIT Margin | 8.78% | 8.94% | 6.83% | 6.27% | 9.77% | 11.62% |
Effective Tax Rate | 21.06% | 13.77% | 6.96% | 0.61% | 14.57% | 1.21% |
Revenue as Reported | 2,750 | 2,371 | 2,174 | 2,123 | 2,078 | 1,815 |
Advertising Expenses | - | 27.74 | 20.64 | 12.16 | 5.36 | 2.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.